Charme Capital Partners

Veritas Intercontinental, S.L., founded in 2004 and based in Madrid, Spain, specializes in whole genome sequencing and genetic testing services. The company provides a range of tests, including myGenome, which assesses risks for hereditary diseases and medication responses; myNewbornDNA, which offers insights into genetic diseases in newborns; myCancerRiskDNA, focused on cancer risk assessment; and myDiagnostic for those showing symptoms of hereditary genetic conditions. Veritas aims to empower individuals to enhance their health and longevity through actionable genetic information. It was established to extend the availability of whole genome sequencing beyond the United States and has garnered recognition from leading technology and health organizations for its innovations and contributions to the field of genomics.

Veritas Intercontinental, S.L., founded in 2004 and based in Madrid, Spain, specializes in whole genome sequencing and genetic testing services. The company provides a range of tests, including myGenome, which assesses risks for hereditary diseases and medication responses; myNewbornDNA, which offers insights into genetic diseases in newborns; myCancerRiskDNA, focused on cancer risk assessment; and myDiagnostic for those showing symptoms of hereditary genetic conditions. Veritas aims to empower individuals to enhance their health and longevity through actionable genetic information. It was established to extend the availability of whole genome sequencing beyond the United States and has garnered recognition from leading technology and health organizations for its innovations and contributions to the field of genomics.